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Sunita Sruvastava, MD, Matthew Eagleton, MD, and Daniel Clair, MD, Cleveland, Ohio
Purpose: Percutaneous angioplasty and stenting (PTAS) is emerging as a therapeutic option for patients with chronic
mesenteric ischemia. This study evaluated patency andmortality, and their relationship between degree of vessel occlusion
(stenotic or totally occluded), stent characteristics, and comorbidities in patients who were treated with PTAS of the
visceral vessels for chronic mesenteric ischemia.
Methods: A retrospective review was performed of the records of all patients who underwent PTAS of the celiac, superior
mesenteric, or inferior mesenteric arteries, or both, for symptomatic chronic mesenteric ischemia between January 2001
and December 2005. Patient demographics, lesion characteristics (stenosis or occlusion), interventional details, and early
and late mortality rates were recorded. Cumulative mortality and patency rates and factors associated with outcomes were
determined using Kaplan-Meier method and Cox proportional hazards modeling.
Results: Eighty-seven mesenteric vessels (57 superior mesenteric, 23 celiac, and 7 inferior mesenteric arteries) were treated
in 65 patients (29men and 36women). Completely occluded vessels were treated in 18 patients (28%), and>60% stenosis
was treated in 47 patients (72%). Mesenteric angina was the most common symptom (97%). For the entire series, the
cumulative 1-year results were primary patency, 65% (95% confidence interval [CI], 50%-80%); primary assisted patency,
97% (95% CI, 92%-100%); secondary patency, 99% (95% CI, 96%-100%); and survival, 89% (95% CI, 80%-98%). All
deaths occurred<60 days after treatment. The endovascular treatment of visceral artery occlusion was not associated with
diminished patency or survival, irrespective of stent size or number. Patients requiring bowel resection were less likely to
survive than those who did not (odds ratio [OR], 26; 95% CI, 3.5-192; P < .001). One-year primary patency was worse
among patients with chronic obstructive pulmonary disease (OR, 3.2; 95% CI, 1.4-7.7; P  .009) or who had femoral
access (OR, 3.0; 95% CI, 1.1-7.9; P  .015).
Conclusions: For patients with chronic mesenteric ischemia, the results of endovascular treatment of occluded mesenteric
arteries are indistinguishable from those treated for stenotic vessels. Patients requiring bowel resection are less likely to
survive, and those with chronic obstructive pulmonary disease or who had femoral access have higher reintervention rates.
(J Vasc Surg 2008;47:485-91.)Percutaneous transluminal angioplasty and stenting
(PTAS) of the visceral arteries is an evolving and viable
alternative for treatment of chronic mesenteric ischemia
(CMI).1,2 Although subintimal angioplasty or recanaliza-
tion of totally occluded vessels is a well-know technique for
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doi:10.1016/j.jvs.2007.11.046treating totally occluded coronary arteries,3 iliac arteries,4
and lower extremity vessels,5 this technique is not fre-
quently used in those patients with chronically occluded
visceral arteries. Resch et al6 previously described a small
series of patients who had completely occluded visceral
vessels revascularized by PTAS. There are several percep-
tions about why endoluminal revascularization of totally
occluded visceral vessels is sometimes avoided, including
increased technical difficulty, higher incidence of restenosis
due to increased plaque burden, and potentially increased
complications such as embolization or dissection. In addi-
tion, open surgical revascularization allows one to visualize
and inspect the intra-abdominal organs and intestines for
the sequelae of embolization.
Although previous series have compared open surgical
revascularization and PTAS of visceral arteries for occlusive
disease,7,8 the specific factors that may be responsible for
restenosis, morbidity, mortality, and loss of patency in
those patients who have undergone PTAS of the visceral
arteries have not yet been evaluated. In addition to total
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tween patency and stent type, diameter, and number of
vessels treated for CMI has not been previously evaluated
to our knowledge. In this study, we evaluate patency and
mortality, and their relationship between degree of vessel
occlusion (partially or totally occluded), stent characteris-
tics, and comorbidities in patients who were treated with
PTAS and stenting of the visceral vessels for CMI.
METHODS
Patients. All patients who underwent PTAS for CMI
between January 2001 and December 2005 by members of
our department were prospectively entered into a comput-
erized database. We performed a retrospective review of
hospital records of consecutive patients with CMI who
underwent PTAS. Patients with aortic dissections, concom-
itant aneurysm repair, nonocclusive mesenteric ischemia,
previous mesenteric PTA or stenting, or both, and acute
mesenteric ischemia were excluded from analysis. Records
were reviewed for patient demographics, preoperative and
postoperative symptoms, and duplex ultrasound (DUS)
findings. Operative notes and angiograms were reviewed
for each vessel treated, degree of stenosis or total occlusion,
and stent type and size. This study had approval of our
Institutional Review Board.
Demographics. Patient demographics and symptoms
are listed in Table I (online only). Most patients presented
with intestinal angina (95.4%), but 67.7% also had weight
loss, and 26.4% had bowel dysfunction (diarrhea or consti-
pation). Eighty-seven blood vessels were treated in 65
patients.
Procedural details. Preoperative evaluation included
physical examination, DUS imaging or computed tomog-
raphy scan, or both, followed by arteriography. The DUS
criteria for stenosis and restenosis were adapted from crite-
ria previously described by Moneta et al9 and Zwolak et
al.10 Stenosis 60% was considered hemodynamically sig-
nificant for therapy and was determined from digital sub-
traction arteriography (DSA) irrespective of the vessel
treated. All patients treated had multivisceral occlusive
disease and were first-time procedures.
Arteriographic access was obtained through either a
transfemoral (29.9%) or transbrachial approach (70.1%).
After wire and sheath placement, a flush aortogram was
taken, followed by systemic heparinization. Selective vis-
ceral vessel cannulation was usually obtained with a re-
versed curve or angled catheter, and each mesenteric out-
flow bed was evaluated for collateral circulation and distal
disease. For stenotic vessels, the lesion was usually crossed
with a 0.035-in glide wire after placement of a 5F or 6F
sheath near the lesion.
Once the lesion was crossed, it was predilated if neces-
sary, followed by placement of a premounted balloon-
expandable stent or a self-expandable stent. Totally oc-
cluded vessels were usually recanalized with a 0.035-in
floppy glide wire and a multipurpose or angled glide cath-
eter. If this was not possible, then a long sheath or guide
catheter was placed next to the occluded vessel for addi-tional support. The vessels were then recanalized by direct
wire passage or subintimal recanalization, and angiographic
confirmation was done to assure the wire re-entered a
patent distal lumen. Predilatation and stenting were accom-
plished as described. All stents placed were oversized by
approximately 10%. Balloon expandable stents were placed
for orifice lesions, and self-expanding stents were placed for
nonorifice lesions in areas of curves. All patients received
aspirin and clopidogrel postoperatively.
Postoperative treatment follow-up included a history,
physical examination, and DUS imaging at 1 month, 3
months, and every 6months thereafter. All patients’ clinical
symptoms and weight gain were recorded at each visit. If
symptoms returned or DUS imaging suggested restenosis
60%, patients underwent repeat diagnostic angiograms.
Statistical analysis. Patient demographics analyzed
included age, sex, preoperative symptoms, history of previ-
ous vascular surgery, coronary artery disease (CAD), hyper-
tension, congestive heart failure (CHF), chronic obstruc-
tive pulmonary disease (COPD), history of stroke, renal
failure, diabetes mellitus, and history of tobacco use. Pro-
cedural details analyzed included the specific vessel treated,
number of vessels treated, number of stents placed per
vessel, type of stent used, and access location. The outcome
measures analyzed were cumulative primary, primary as-
sisted, and secondary patency, and death. Patencies were
determined by Society for Vascular Surgery guidelines.11
Arteriograms and operative notes were reviewed for stent
characteristics, and degree of stenosis was categorized as
severely stenotic or occluded.
To assess the relationship between time to patency loss
or death and other risk factors, univariable and multivari-
able time-to-event models were fit. Kaplan-Meier methods
were used to perform univariable comparisons, and statis-
tical significance was based on the log-rank. For multivari-
able evaluations, the P values are from Wald tests in Cox
regressionmodels (testing whether the hazards are similar),
except where noted, when Score tests provided more reli-
able estimates when undefined risk estimates existed.
Because many patients may have more than one vessel
treated and more than one stent placed, marginal Cox
proportional hazards models were used to correct for the
correlation within a patient on patency, and traditional Cox
proportional hazards models were used to evaluate mortal-
ity, which had one observation per patient. A stepwise
model was used to select the variables in the multivariable
model, from a pool of variables that had a univariable value
of P  .20.
The generalized estimating equation logistic regression
model and the Fisher exact test were used to evaluate
whether the certain preoperative and perioperative mea-
sures were associated with whether vessels were occluded or
stenotic. Odds ratios (OR) and 95% confidence intervals
(CI) were estimated to compare risk levels between groups.
Analysis of patency was performed at a per-stent level, and
analysis of mortality was performed by patient. In the
mortality analysis, factors that differed by stent were
summed or averaged to allow one measurement per pa-
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comparisons. Analyses were performed using SAS software
(SAS Institute, Cary, NC), and plots were created using R
software.12
RESULTS
Sixty-five patients (29 men, 36 women) had 87 mesen-
teric vessels treated (average, 1.34 vessels per patient). The
mean age was 70 years (range, 44-89 years). The specific
vessels treated were 57 superior mesenteric arteries (SMA;
65.5%), 23 celiac arteries (CA; 26.4%), and seven inferior
mesenteric arteries (IMA; 8.1%). In 22 patients, the follow-
ing combinations of two vessels were treated: SMA andCA,
19; SMA and IMA, two; and IMA and CA, one. No patient
had more than two vessels treated. Completely occluded
vessels were treated in 18 patients (28%), and60% steno-
sis was treated in 47 patients (72%).
Balloon-expandable stents were placed in 80 vessels
(91.5%), and self-expandable stents were placed in seven
(8.5%). Several patients had more than one stent placed per
vessel for a total 137 stents placed in 87 vessels. In 12
patients, two stents were placed in a single vessel, three
stents were placed in one patient, and four stents were
placed in 1 patient. The mean  SD diameter of stents
placed was 6.5  2.2 mm, and the average length was
18.8 6.4mm; for two patients (3 vessels), information on
the stent length or diameter used was not available. Of the
four isolated IMA stents placed, three of the patients had
occluded celiac and superior mesenteric arteries that could
not technically be recanalized, and one patient had an
incomplete marginal arcade with a stenotic IMA and isch-
emic colitis.
Outcomes. Symptom relief was immediate in 85% of
the patients, and 75% of patients had symptom relief be-
yond 1 year. The overall morbidity rate was 30.8%. The
most common complication was access site hematoma/
pseudoaneurysm/thrombosis (15.4%), followed by bowel
infarction (4.6%). All deaths occurred60 days after treat-
ment. The in-hospital/30-day mortality rate was 7.7%.
Fig 1. Kaplan-Meier cumulative 1-year rates for primary, primary-
assisted, and secondary patency.Three of the five in-hospital/30-day deaths were due topostintervention bowel ischemia requiring resection; all of
these patients died from sepsis and multisystem organ
failure. One patient died from pneumonia on postoperative
day 17, and one died from a stroke on postoperative day 26.
In the other patient who underwent bowel resection, toxic
mega-colon from Clostridium difficile colitis developed 6
weeks postoperatively.
The cumulative 1-year patency rates (Fig 1) were pri-
mary patency, 65% (95% CI, 50%-80%); primary assisted
patency, 97% (95% CI, 92%-100%); and secondary patency,
99% (95% CI, 96%-100%). All primary patency losses oc-
curred9 months of therapy, and all patients were treated
by reintervention with balloon angioplasty or stenting, or
both. Three of the patients who underwent reintervention
required an additional stent, and two patients required two
additional stents. In the patient who had a completely
occluded stent, recurrent symptoms developed and stent
recanalization was done without the use of thrombolytics.
Univariable comparisons of preoperative risk factors are
listed in Table II. For preoperative risk factors, those pa-
tients who had hypertension, COPD, and bowel dysfunc-
tion all had significantly diminished patency rates. Compli-
cations and operative risk factors associated with primary
patency are listed in Tables III, A (online only), III, B, and
III, C (online only). No specific complication was associ-
ated with diminished patency, but for operative parameters,
those who had femoral access were more likely to lose
primary patency (78.2% [95% CI, 63.6%-92.9% vs 43.5%,
95% CI, 16.4%-70.6%]; P  .03). There was no difference
in patency rate irrespective of vessel treated (CA, SMA,
IMA), stent type, number of stents placed, size of stent
placed, diameter and length of stent placed, or number of
vessels treated in each patient. Multivariable regression
analysis demonstrated the presence of bowel dysfunction
(hazard ratio [HR] 10.8; 95% CI, 1.7-70.3; P  .013) or
femoral access (HR, 4.6; 95% CI, 1.6-13.8; P  .006) had
increased risk of primary patency loss.
The cumulative 1-year survival rate was 89% (95% CI,
80%-98%; Fig 2). All deaths occurred 60 days of treat-
ment. There was no difference in patency, complication, or
survival rate irrespective of vessel treated (CA, SMA, IMA),
stent type, number of stents placed, size of stent placed,
diameter and length of stent placed, or number of vessels
treated in each patient. For preoperative risk factors, those
patients who had hypercholesterolemia had 1-year sur-
vival rates of 100.0% (95% CI, 100.0%-100.0%) vs 81.6%
(95% CI, 66.8%-96.4%; P  .05), and there was a trend
towards decreased survival in those who had COPD of
94.4% (95% CI, 86.8%-100.0%) vs 74.7% (95% CI, 49.4%-
99.9%; P  .09). No patient who underwent bowel resec-
tion after the procedure survived (P  .001). Femoral
artery access as opposed to brachial artery access was the
only operative risk factor that trended towards decreased
survival (83.7% [95% CI, 70.4%-97.0%] vs 100.0% [95%
CI, 100.0%-100.0%]; P  .09). Multivariable modeling
was not performed owing to the low incidence of death in
the cohort.
tructiv
ratio.
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ing stenotic and completely occluded vessels are demon-
strated in Fig 3. There was an initially greater loss of
primary patency in totally occluded vessels compared with
stenotic vessels; however, by 1 year the Kaplan-Meier cu-
mulative primary patency rates were equal at 63% (95% CI,
45%-81%) vs 70% (95% CI, 43%-96%; P .68). Risk factor
comparison between stenotic and occluded vessels is dem-
onstrated in Tables III, A (online only), III, B, and III, C
(online only). The following risk factors had statistically
Table II. Comparison of primary patency rates/stent and
Factor Group N
Sex Male 36
Female 51
Smoking No 17
Yes 70
Hypertension No 7
Yes 80
CAD No 24
Yes 63
COPD No 65
Yes 22
Renal disease No 68
Yes 19
Hypercholesterolemia No 48
Yes 39
Diabetes No 72
Yes 15
Pain No 3
Yes 84
Weight Loss No 29
Yes 58
Diarrhea No 64
Yes 23
Bowel dysfunction No 77
Yes 10
GI bleeding No 79
Yes 8
Previous vascular surgery No 74
Yes 13
CAD, Coronary artery disease; CI, confidence interval; COPD, chronic obs
aScore test.
Table III, B. Comparison of associations between vessel o
Risk factor Level Total
Occluded
No. %
Hematoma No 81 21 25
Yes 6 0 0
GI bleeding No 84 18 21
Yes 3 3 100
False aneurysm No 83 18 21
Yes 4 3 75
Bowel resection No 83 19 22
Yes 4 2 50
Diarrhea No 84 21 25
Yes 3 0 0
CI, Confidence interval; GI, gastrointestinal; NA, not applicable; OR, odds
aP values are from generalized estimating equation logistic regression, excedifferent incidences in stenotic compared with occluded ves-sels: COPD, postoperative gastrointestinal hemorrhage, and
postoperative pseudoaneurysm formation. However, these
differences between groups did not impact the multivariable
patency and survival results. Also, there was no difference in
1-year cumulative survival rates (Fig 2) between completely
occluded and partially occluded vessels (91% [95% CI, 82%-
100%] vs 84% [95% CI, 62%-100%]; P .43).
DISCUSSION
The first description of treating mesenteric vessels by
perative risk factors
nths, % (range) HR (95% CI) Reference
(43.4-89.2) 1.0 .86
(43.3-83.8) 1.09 (0.41-2.90)
(33.8-98.9) 1.0 .97
(48.7-81.9) 0.97 (0.25-3.78)
(100.0-100.0) 1.0 .03
(47.1-78.5) 2.20 (1.09-4.46)
(32.8-98.1) 1.0 .42
(49.0-81.8) 1.51 (0.55-4.18)
(54.8-88.1) 1.0 .008
(14.8-76.6) 3.23 (1.36-7.67)
(50.8-83.9) 1.0 .069
(33.6-92.1) 2.26 (0.94-5.45)
(43.9-86.0) 1.0 .74
(41.4-86.6) 0.85 (0.33-2.20)
(51.6-85.6) 1.0 .26
(31.3-87.4) 1.96 (0.61-6.29)
(0.00-0.00) 1.0 .24
(51.9-81.8) 0.45 (0.12-1.68)
(41.2-87.8) 1.0 .76
(48.8-85.7) 0.86 (0.32-2.29)
(37.9-76.4) 1.0 .11
(65.0-100.0) 0.26 (0.05-1.36)
(54.3-84.6) 1.0 .032
(0.00-0.00) 4.61 (1.14-18.53)
(46.1-78.1) 1.0 .15a
(100.0-100.0) NA
(52.2-83.5) 1.0 .31
. (0.00) 1.71 (0.61-4.84)
e pulmonary disease; GI, gastrointestinal; HR, hazard ratio.
sion and complications
Stenotic
OR (95% CI) PaNo. %
60 74.1 1.0 .33F
6 100.0 NA
66 78.6 1.0 .013F
0 0.00 NA
65 78.3 1.0 .016
1 25.0 10.69 (1.55-73.70)
64 77.1 1.0 .47
2 50.0 2.46 (0.21-28.79)
63 75.0 1.0 .99F
3 100.0 NA
re marked by an F, where the Fisher exact test was used.preo
12 mo
66.3
63.6
66.3
65.3
100.0
62.8
65.5
65.4
71.4
45.7
67.4
62.9
64.9
64.0
68.6
59.3
0.00
66.9
64.5
67.3
57.2
85.0
69.4
0.00
62.1
100.0
67.9cclu
.9
.00
.4
.0
.7
.0
.9
.0
.0
.00percutaneous angioplasty was in 1980 by Furrer et al.13 We
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fully were treated by recanalizing chronically occluded vis-
ceral vessels with PTAS for CMI.14 Since these publica-
tions, numerous studies have documented the success of
PTAS for CMI.15-17 The purpose of this study was to
extend these data by looking at midterm and 1-year out-
comes to compare the results of PTAS of completely oc-
cluded vessels with those in severely stenotic vessels, and to
evaluate predictors of patency.
Our primary patency rate of 69% was less than expected
but similar to other contemporary series that reported
restenosis rates of 20% at 6 months1 and 53% at 1 year.8 The
reasons for a high reintervention rate can be multifactorial.
One possible explanation is this disease process is an exten-
sion of aortic atherosclerosis and there is a large degree of
plaque burden. It is possible that stent grafts may offer a
better solution, but to date, no stent has been approved for
this location, let alone stent graft, and trials will need to be
conducted. Current concerns over the routine use of stent
grafts for visceral occlusive intervention include the need
Fig 2. Kaplan-Meier cumulative 1-year survival for all groups for
vessel occlusion.
Fig 3. Kaplan-Meier cumulative 1-year primary patency for ste-
notic vs occluded vessels.for larger access sheaths, decreased size availabilities, con-cern over collateral/branch coverage, and increased reste-
nosis rates.
Although several risk factors, such as hypertension,
COPD, constipation, and femoral access, were associated
with decreased primary patency rates, multifactorial analysis
found that bowel function and femoral access were the
most significant risk factors to predict decreased patency.
The decreased patency from femoral access possibly relates
to technical details of an antegrade vs retrograde access for
treatment. In general, we have adapted an antegrade ap-
proach from brachial access as the preferred method of
access. From a brachial approach, the trajectory for catheter
manipulation is simplified. Furthermore, the angles in a
severely down-sloping visceral artery can preclude precise
stent placement from a femoral approach.
There was no difference in complication rates from
access sites, although this may be a reflection of the small
number. The association of decreased patency and bowel
dysfunction may be related to diminished oral intake from
recurrent symptoms, ischemic damage to the myenteric
plexi, or possibly persistent bowel dysfunction in those
patients who had undetected microembolization.
A major objective of this study was to demonstrate that
recanalization PTAS of totally occluded visceral vessels is
not only technically feasible but also has satisfactory out-
come data. Cumulative patency rates found that there were
similar primary patency rates of both stenotic and occluded
vessels in addition to survival. Nevertheless, given that the
in-hospital or 30-day mortality rate was 7.7% and three
patients required bowel resection for segmental infarction,
embolic protection may potentially prevent this complica-
tion in both stenotic and occluded vessels.
We also evaluated several different types and lengths of
stents used in this study. Most of the stents used were
balloon-expandable stents, which indicates that most of the
disease was an extension of surrounding aortic atheroscle-
rosis. Self-expanding stents were usually reserved for tortu-
ous vessels beyond the orifice. There was no difference in
patency rates irrespective of stent type, size, or number and
no difference in patency rates between any of the vessels
treated (CA, SMA, and IMA). Finally, intervening on more
than one vessel and placing more than one stent in a vessel
also did not contribute to diminished patency. There has
been some debate about whether more than one vessel
should be revascularized18,19 in open mesenteric bypass
patients. Although anecdotal, given the diminished primary
patency rates, we recommend PTAS of all stenotic vessels if
technically feasible.
The in-hospital or 30-day mortality rate was 7.7%, and
the 1-year cumulative survival rate was 89%. These results
compare favorably with other contemporary series of open
and percutaneous treatment of CMI.1,7,8,20,21 All patients
who died had patent stents at the time of their death. Three
of the five in-hospital deaths occurred in patients who
ended up with bowel resections, and these patients were
26 times more likely to die. It is possible that in the
patients who required bowel resection, embolization
developed as a result of the intervention; however,
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emboli. Nevertheless, the segmental nature of the infarc-
tion cannot exclude microembolism as an etiologic fac-
tor. Another possible explanation is that the patients
were not properly diagnosed with an advanced degree of
ischemia that progressed to an acute on chronically
ischemic scenario; perhaps these patients would have
been better off undergoing abdominal exploration and
open surgical revascularization.
No one specific risk factor was associated with a higher
incidence of death other than the complication of bowel
infarction, and this included patients who had treatment of
a complete occlusion. Patients who had hypercholesterol-
emia appeared to have a survival advantage, and this may
have been related to these patients receiving aggressive
medical intervention with statins. The small number of
deaths made multifactorial analysis inconclusive. We did
not measure statin use in this study, but it would be
interesting to see if this also led to an advantage or protec-
tive affect from restenosis.
This study does have several limitations. It is retro-
spective in nature, and the small number of events may
have limited the ability to detect important predictive
factors. Further, the large number of stents used made
evaluation of this factor less meaningful. Nevertheless, to
our knowledge it is the largest series to date document-
ing the usefulness of PTAS for chronic mesenteric occlu-
sive disease and includes a cohort of patients (totally
occluded visceral arteries) who were previously thought
to be unacceptable candidates for this therapy. This is
also important given that many of these patients have
serious medical comorbidities, including 70% with sig-
nificant coronary artery disease. Finally, there are no
widely established DUS criteria for accepting “in-stent”
restenosis, possibly missing some restenotic lesions. In
this study, however, the arteriographic DUS findings
were consistent with the DUS findings.
CONCLUSION
Endovascular treatment of completely occluded mes-
enteric arteries has similar patency and survival rates as
those treated for stenotic vessels and can be considered a
first-line therapy. High restenosis rates for all mesenteric
interventions, and our results presented here, suggest bra-
chial access is superior to femoral access. In addition, newer
therapies such as drug-coated stents and newer stent grafts
should be evaluated to improve on the high restenosis rates.
Finally, embolization is a potential problem that can lead to
bowel infarction, and embolic protection should be consid-
ered.
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RECOUP THE LOUPES 
Despite extremely limited resources, surgeons in developing countries work to provide their 
patients with the best possible care. For many of these surgeons, technology such as loupes, 
which facilitate delicate procedures, is simply out of reach.  
One year ago, Loupes Around The World distributed its first pair of loupes to a plastic surgeon
in Phnom Penh, Cambodia. Before Loupes Around The World, this surgeon commonly 
repaired cleft lips and palates, and treated trauma patients with maxillofacial injuries without 
the benefit of surgical magnification. Since then, this not-for-profit organization has provided 
loupes to surgeons from Panama to India and continues to receive requests from surgeons 
around the world.  
Loupes Around The World is now recycling donated loupes via a program called “Recoup the 
Loupes.” Surgeons with unused loupes are asked to send them to the foundation; there, repairs 
can be made to adjustable loupes, and the telescopes from fixed loupes can be installed into 
new lenses and frames. For fixed loupes, optical measurements are taken to ensure that the 
loupes will meet the needs of each individual surgeon. 
Please send your unused loupes to:  
David C. Knight, M.D., F.A.C.S. 
Loupes Around The World 
c/o Surgical Associates of Waterbury 
1211 West Main St. 
Waterbury, CT 06708 
Loupes Around The World accepts loupes made by any manufacturer. For more information 
about Loupes Around The World, as well as information about how to contribute, please visit: 
www.loupesaroundtheworld.org. Upon receiving loupes, a letter of acknowledgment will be 
sent to the donor for tax purposes. Loupes Around the World is a 501(c)3 tax-exempt 
organization.  
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Variable No. %
Risk factors
Hypertension 59 90.8
Tobacco 51 78.5
Coronary artery disease 46 70.7
Hypercholesterolemia 28 43.8
COPD 16 24.6
Previous vascular surgery 13 20.0
Renal insufficiency 12 18.5
Diabetes mellitus 9 13.8
Symptoms
Intestinal angina 62 95.4
Weight loss 44 67.7
Diarrhea 17 26.2
Hematochezia/melena 5 7.7
COPD, Chronic obstructive pulmonary disease.
Table III, A (online only). Comparison of associations between vessel occlusion and preop risk factors
Risk factor Level Total
Occluded Stenotic
OR (95% CI) PaNo. % No. %
Gender Male 36 8 22.2 28 77.8 1.0 .52
Female 51 13 25.5 38 74.5 1.42 (0.48-4.19)
Smoking No 17 4 23.5 13 76.5 1.0 .87
Yes 70 17 24.3 53 75.7 1.12 (0.27-4.63)
Hypertension No 7 1 14.3 6 85.7 1.0 .61
Yes 80 20 25.0 60 75.0 1.78 (0.19-16.41)
CAD No 24 6 25.0 18 75.0 1.0 .83
Yes 63 15 23.8 48 76.2 0.88 (0.26-2.92)
COPD No 65 12 18.5 53 81.5 1.0 .034
Yes 22 9 40.9 13 59.1 3.42 (1.10-10.67)
Renal Disease No 68 18 26.5 50 73.5 1.0 .53
Yes 19 3 15.8 16 84.2 0.64 (0.16-2.57)
Hypercholesterolemia No 48 14 29.2 34 70.8 1.0 .36
Yes 39 7 18.0 32 82.1 0.59 (0.19-1.82)
Diabetes mellitus No 72 18 25.0 54 75.0 1.0 .64
Yes 15 3 20.0 12 80.0 0.67 (0.13-3.54)
Pain No 3 0 0.00 3 100.0 1.0 .99F
Yes 84 21 25.0 63 75.0 NA
Discomfort No 58 13 22.4 45 77.6 1.0 .42
Yes 29 8 27.6 21 72.4 1.56 (0.53-4.59)
Weight loss No 29 7 24.1 22 75.9 1.0 .86
Yes 58 14 24.1 44 75.9 0.90 (0.29-2.82)
Diarrhea No 64 13 20.3 51 79.7 1.0 .26
Yes 23 8 34.8 15 65.2 1.97 (0.61-6.33)
Bowel dysfunction No 77 21 27.3 56 72.7 1.0 .11F
Yes 10 0 0.00 10 100.0 NA
GI bleeding No 79 20 25.3 59 74.7 1.00 (1.00-1.00) .34
Yes 8 1 12.5 7 87.5 0.38 (0.05-2.80)
Previous vascular surgery No 74 19 25.7 55 74.3 1.0 .54
Yes 13 2 15.4 11 84.6 0.60 (0.12-3.08)
CAD,Coronary artery disease;CI, confidence interval;COPD, chronic obstructive pulmonary disease;GI, gastrointestinal;NA, not applicable;OR, odds ratio.
aP values are from generalized estimating equation logistic regression, except where marked by an F, where the Fisher exact test was used.
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Risk factor Level Total
Occluded Stenotic
OR (95% CI) PaNo. % No. %
SMA No 29 6 20.7 23 79.3 1.0 .59
Yes 58 15 25.9 43 74.1 1.28 (0.52-3.14)
IMA No 80 21 26.3 59 73.8 1.0 .19F
Yes 7 0 0.00 7 100.0 NA
Celiac artery No 64 15 23.4 49 76.6 1.0 0.77
Yes 23 6 26.1 17 73.9 1.16 (0.44-3.05)
1 stent used No 71 17 23.9 54 76.1 1.0 0.72
Yes 14 4 28.6 10 71.4 0.70 (0.11-4.66)
Mean stent diameter, mm 6 19 5 26.3 14 73.7 1.0
6-6.99 33 8 24.2 25 75.8 0.70 (0.17-2.95) .63
7 32 8 25.0 24 75.0 1.00 (0.31-3.25) .99
Mean stent length, mm 18 28 7 25.0 21 75.0 1.0 .60
18-19.99 27 5 18.5 22 81.5 0.70 (0.22-2.21) .54
20 30 9 30.0 21 70.0 1.49 (0.45-4.86) .51
Interventions, No. 1 64 17 26.6 47 73.4 1.0 .64
2 15 2 13.3 13 86.7 0.47 (0.10-2.35) .36
3 8 2 25.0 6 75.0 1.08 (0.20-5.88) .93
Brachial access No 17 1 5.9 16 94.1 1.0 .086
Yes 70 20 28.6 50 71.4 6.32 (0.77-51.76)
Femoral access No 61 18 29.5 43 70.5 1.0 .082
Yes 26 3 11.5 23 88.5 0.30 (0.08-1.16)
CI, confidence interval; IMA, inferior mesenteric artery; OR, odds ratio; SMA, superior mesenteric artery.
aP values are from generalized estimating equation logistic regression, except where marked by an F, where the Fisher exact test was used.
